Invirase Capsules (Hard Gelatin)
Saquinavir
200mg
F. Hoffmann-La Roche Ltd.
| Pack size | 270's Bottle |
|---|---|
| Dispensing mode | POM |
| Source | SWITZERLAND |
| Agent | IBN KHALDOON DRUG STORE |
| Retail Price | 1685.00 AED |
Available as:
Indications
Invirase Capsules (Hard Gelatin) is used for:
HIV infection
Adult Dose
Oral
HIV infection
Adult: In combination w/ other antiretrovirals: 1,000 mg bid w/ ritonavir 100 mg bid. Treatment-naive patients: 500 mg bid (w/ ritonavir 100 mg bid) for the 1st 7 days of treatment then increase to 1,000 mg bid.
Child Dose
HIV Infection
Indicated in combination with ritonavir and other antiretrovirals (ARTs) for treatment of HIV-1 infection
<16 years: Safety and efficacy not established
>16 years: 1000 mg (plus ritonavir 100 mg) PO q12hr
For patients already taking ritonavir 100 mg BID as part of their ART regimen, no additional ritonavir is needed
Renal Dose
Administration
Should be taken with food. Take w/ meals or up to 2 hr after meals
Contra Indications
Hypersensitivity. Congenital or documented acquired QT prolongation, complete AV block (including patients at high risk) w/o implanted pacemakers, electrolyte disturbance (particularly uncorrected hypokalaemia), clinically relevant bradycardia or heart failure w/ reduced left-ventricular ejection fraction, history of symptomatic arrhythmia. Severe hepatic impairment. Lactation.
Concomitant admin w/ drugs that prolong QT or PR interval, sedative/hypnotics (triazolam, oral midazolam), HMG-CoA reductase inhibitors (simvastatin, lovastatin), ergot alkaloids, rifampicin, quetiapine, alfuzosin.
Precautions
Patient w/ haemophilia A and B, pre-existing conduction system abnormalities. Mild to moderate hepatic or severe renal impairment. Pregnancy.
Monitoring Parameters
Monitor ECG, serum K and Mg levels, triglycerides, cholesterol, viral load, CD4 count and glucose.
Pregnancy-Lactation
Pregnancy
Prospective pregnancy data from the APR are not sufficient to adequately assess a drug-associated risk of birth defects or fetal outcomes; limited number of reports on use of drug during pregnancy has been submitted to the APR and number of exposures to drug is insufficient to make a risk assessment compared to a reference population
Animal data
In animal reproduction studies with saquinavir, no evidence of adverse developmental effects were observed at highest achievable plasma exposures (AUC) in both rats and rabbits, resulting in exposures approximately 25% of those obtained in humans at recommended human dose (RHD) combined with drug; therapy should be administered during pregnancy only if potential benefit justifies potential risk to fetus
Lactation
The Centers for Disease Control and Prevention recommends that HIV-infected mothers in US not breastfeed their infants to avoid risking postnatal transmission of HIV-1
There are no data available regarding presence of drug in human milk, effects on breastfed infant, or on milk production
Because of potential for HIV-1 transmission (in HIV-negative infants), developing viral resistance (in HIV-positive infants) and adverse reactions in breastfed infants similar to those seen in adults, instruct mothers not to breastfeed if receiving therapy
Interactions
May increase plasma concentration of fusidic acid. Increased risk of bleeding w/ anticoagulants (e.g. rivaroxaban). May alter plasma concentrations of warfarin.
Potentially Fatal: Potentially prolonged or increased sedation and resp depression w/ sedative/hypnotics (oral midazolam, triazolam). Increased risk of myopathy including rhabdomyolysis w/ HMG-CoA reductase inhibitors (simvastatin, lovastatin). Increased potential for acute ergot toxicity w/ ergot alkaloids (e.g. ergotamine, dihydroergotamine, ergonovine, methylergonovine). Increased risk of severe hepatotoxicity w/ rifampicin.
Risk of coma w/ quetiapine. Risk of hypotension w/ alfuzosin. Additive effect on QT or PR interval prolongation w/ antiarrhythmics (amiodarone, bepridil, dofetilide, flecainide, systemic lidocaine, propafenone, quinidine) neuroleptics (e.g. pimozide, clozapine, haloperidol), sildenafil (if used for pulmonary arterial HTN), antidepressant (trazodone), some anti-infectives (clarithromycin, erythromycin, halofantrine, pentamidine), some antihistamines (terfenadine, astemizole).
Adverse Effects
Side effects of Saquinavir :
1-10%
Rash
Hyperglycemia
Diarrhea
Abdominal discomfort
Nausea
Abdominal pain
Buccal mucosa ulceration
Paresthesia
Weakness
Increased CPK
<1%
Headache
Confusion
Seizures
Ataxia
Pain
Stevens-Johnson syndrome
Hypoglycemia
Hyper- & hypokalemia
Low serum amylase
AML
Hemolytic anemia
Thrombocytopenia
Jaundice
Ascites
Mechanism of Action
Saquinavir is a selective, competitive, reversible HIV protease inhibitor that interferes w/ the formation of essential proteins and enzymes. It blocks virus maturation and causes non-functional, immature and non-infectious virions formation.
Note
Invirase 200mg Capsules (Hard Gelatin) manufactured by F. Hoffmann-La Roche Ltd.. Its generic name is Saquinavir. Invirase is availble in United Arab Emirates.
Farmaco UAE drug index information on Invirase Capsules (Hard Gelatin) is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.